Last updated: 23 July 2019 at 4:33pm EST

Charles R Lamantia Net Worth




The estimated Net Worth of Charles R Lamantia is at least 19.9 千$ dollars as of 7 February 2006. Charles Lamantia owns over 5,000 units of Neurometrix stock worth over 19,950$ and over the last 19 years Charles sold NURO stock worth over 0$.

Charles Lamantia NURO stock SEC Form 4 insiders trading

Charles has made over 2 trades of the Neurometrix stock since 2006, according to the Form 4 filled with the SEC. Most recently Charles exercised 5,000 units of NURO stock worth 47,000$ on 7 February 2006.

The largest trade Charles's ever made was exercising 5,000 units of Neurometrix stock on 7 February 2006 worth over 47,000$. On average, Charles trades about 1,667 units every 0 days since 2006. As of 7 February 2006 Charles still owns at least 5,000 units of Neurometrix stock.

You can see the complete history of Charles Lamantia stock trades at the bottom of the page.



What's Charles Lamantia's mailing address?

Charles's mailing address filed with the SEC is C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM, MA, 02451.

Insiders trading at Neurometrix

Over the last 20 years, insiders at Neurometrix have traded over 14,886,276$ worth of Neurometrix stock and bought 3,074,896 units worth 6,396,868$ . The most active insiders traders include James Edeerfield Capital Lp...Capital Partners, Lp ToplineCapital Management, Llc Mc .... On average, Neurometrix executives and independent directors trade stock every 45 days with the average trade being worth of 133,905$. The most recent stock trade was executed by Thomas T Higgins on 2 May 2024, trading 498 units of NURO stock currently worth 2,226$.



What does Neurometrix do?

neurometrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. the company maintains an active research effort and has several pipeline programs. the company is located in waltham, massachusetts and was founded as a spinoff from the harvard-mit division of health sciences and technology in 1996. for more information, please visit neurometrix.com. neurometrix markets the following products: quell® wearable pain relief technology™ quell is 100% drug free wearable technology that has changed the lives of people suffering with chronic pain. it combines clinical strength neurostimulation to treat pain with an easy-to-use app that helps people manage pain and reclaim their lives. quell is doctor recommended and designed for people with chronic back pain, arthritic pain, nerve pain, leg and foot pain, among other chronic pain conditions. quell launc



Complete history of Charles Lamantia stock trades at Neurometrix

インサイダー
取引
取引
合計金額
Charles R Lamantia
ディレクター
オプション行使 47,000$
7 Feb 2006


Neurometrix executives and stock owners

Neurometrix executives and other stock owners filed with the SEC include: